Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States.
Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.
The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.15 Increased by +73.68% | -0.36 Increased by +58.33% |
| Mar 14, 24 | -0.20 Increased by +64.91% | -0.34 Increased by +41.18% |
| Nov 9, 23 | -0.44 Increased by +15.38% | -0.28 Decreased by -57.14% |
| Aug 10, 23 | -0.37 Increased by +42.19% | -0.07 Decreased by -428.57% |
| May 11, 23 | -0.57 Increased by +16.18% | -0.55 Decreased by -3.64% |
| Mar 23, 23 | -0.57 Increased by +12.31% | -0.49 Decreased by -16.33% |
| Nov 8, 22 | -0.52 Increased by +30.67% | -0.55 Increased by +5.45% |
| Aug 9, 22 | -0.64 Increased by +13.51% | -0.57 Decreased by -12.28% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.81 M Increased by +71.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 3.60 M Increased by +N/A% | -8.79 M Decreased by -126.97% | Decreased by -244.16% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -21.58 M Increased by +5.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | 67.48 M Increased by +338.14% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -24.12 M Increased by +20.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 32.57 M Increased by +215.38% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -22.84 M Increased by +29.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -28.33 M Increased by +9.73% | Decreased by N/A% Decreased by N/A% |